Davidson Michael H.

CEO Michael H. Davidson sold 443,707 shares of NAMS at $33.25 (2026-03-02); post-sale holds 174,144 shares (28.2% of prior holdings).

CEO Michael H. Davidson sold 443,707 shares at $33.25 on 2026-03-02, reducing his stake from 617,851 shares to 174,144 shares, representing a -71.8% reduction in holdings. The sale occurred at $33.25, slightly above the current price of $32.83 but well below the 52-week high of $41.45; the stock has declined -14.4% over the prior 90 days. The underlying company posted revenue of $348,000.00 in the latest quarter, net income of $-72,005,000.00, and annual revenue growth of -50.6%, signaling severe operational distress. In his cross-ticker track record, Davidson's 7 prior sells had a 0 of 0 well-timed rate at the 90-day mark, and his 5 most recent trades at NAMS (all sales within 6 days) have measurable outcomes not yet determinable. The rapid succession of five sales within one week, the substantial reduction in personal exposure, combined with sharply negative fundamentals, warrants examination of whether this represents a shift in the insider's confidence in near-term trajectory.

CEO Davidson sells 306,293 shares for $10.6M over 3 days; cuts stake by 63.8% as NAMS reports -$72.0M net loss, -50.6% revenue decline

CEO Michael H. Davidson executed 7 separate sales totaling 306,293 shares for $10,575,091.20 at a blended average price of $34.53 between February 24–26, 2026, reducing his holdings from 480,437 to 174,144 shares (a 63.8% reduction). This concentrated liquidation occurs as NewAmsterdam Pharma reports severe deterioration in fundamentals: latest quarterly revenue of $348,000.00, net loss of $-72,005,000.00, and annual revenue growth of -50.6%. At the current price of $34.28, the stock sits 17.3% below its 52-week high, having declined 17.0% over 90 days. The magnitude of the stake reduction (306.3K shares sold in three days) and the timing during a period of material negative operating performance—coupled with the company's unprofitable status—warrant scrutiny of the underlying business trajectory.

CEO Michael H. Davidson bought 5,000 NAMS shares at $16.27 on 2024-08-20; stock now -31.8% from 52-week high, company posted -86.3% annual revenue decline.

CEO Michael H. Davidson purchased 5,000 shares at $16.27, bringing his total holdings to 209,784 shares. The purchase occurred as NewAmsterdam Pharma faces severe operational headwinds: the company reported quarterly revenue of $2,279,000.00 with a net loss of $-39,007,000.00, and full-year revenue contracted by -86.3% year-over-year. The stock is currently trading -31.8% below its 52-week high and has declined -12.7% over the past 30 days. Davidson's cross-ticker open-market trade history shows 2 prior buys with an average 30-day return of +9.5%, though his single prior NAMS purchase (2024-06-20) is not yet measurable at the 90-day mark. The purchase represents a modest 2.4% increase to his existing holdings in an unprofitable company experiencing dramatic revenue deterioration.

Director Davidson buys 2,500 shares of TENX; holdings rise 656.2% to 2,881 shares; stock down 91.6% from 52-week high.

Director Michael H. Davidson purchased 2,500 shares of Tenax Therapeutics on 2024-08-08, a material increase to his position holdings from 381 shares to 2,881 shares (+656.2% increase in his stake). The purchase occurred at a time when the stock trades at $4.14, down 91.6% from its 52-week high of $49.60, though the stock has recovered 29.8% over the prior 30 days and 15.5% over 90 days. The company's fundamentals present a notable discontinuity: revenue was $0.00 in the latest quarter with annual revenue growth of -100.0%, yet net income was reported at $3,798,840.00, creating an unusual earnings profile for a micro-cap ($8.1M market cap) with a P/E of 0.80. The buy activity is noteworthy given both the magnitude of the relative position increase and the company's shifted revenue trajectory, though without scheduled trading plan disclosure or transaction price context, the circumstances warrant examination.

CEO Davidson bought 5,000 shares at $17.26; stock now $19.63 after -86.3% annual revenue decline

Michael H. Davidson, Chief Executive Officer, purchased 5,000 shares at $17.26 on 2024-06-20, increasing his holdings from 199,784 shares to 204,784 shares. The purchase occurred in a company with severe operational headwinds: annual revenue contracted -86.3% versus the prior fiscal year, the company generated net income of $-93,767,000.00 over its most recent full year, and latest-quarter revenue was only $1,401,000.00. The stock traded at current price $19.63, positioned -19.0% below its 52-week high of $24.23. This insider purchase during a period of substantial revenue deterioration and ongoing losses warrants examination of whether it reflects CEO assessment of fundamental value or other considerations.